Standard BioTools Inc. (LAB)
Standard BioTools Statistics
Share Statistics
Standard BioTools has 378.99M shares outstanding. The number of shares has increased by 0.5% in one year.
| Shares Outstanding | 378.99M |
| Shares Change (YoY) | 0.5% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 74.65% |
| Shares Floating | 364.9M |
| Failed to Deliver (FTD) Shares | 427 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 17.68M, so 4.67% of the outstanding shares have been sold short.
| Short Interest | 17.68M |
| Short % of Shares Out | 4.67% |
| Short % of Float | 9.41% |
| Short Ratio (days to cover) | 13.61 |
Valuation Ratios
The PE ratio is -4.45 and the forward PE ratio is -12.83. Standard BioTools's PEG ratio is 0.1.
| PE Ratio | -4.45 |
| Forward PE | -12.83 |
| PS Ratio | 3.54 |
| Forward PS | 1.9 |
| PB Ratio | 1.31 |
| P/FCF Ratio | -4.07 |
| PEG Ratio | 0.1 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Standard BioTools.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.7, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.7 |
| Quick Ratio | 5.09 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | -0.28 |
| Debt / FCF | -0.22 |
| Interest Coverage | -52.85 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $214.29K |
| Profits Per Employee | $-170.62K |
| Employee Count | 814 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 2.21 |
Taxes
| Income Tax | 573K |
| Effective Tax Rate | -0.41% |
Stock Price Statistics
The stock price has increased by -54.33% in the last 52 weeks. The beta is 1.53, so Standard BioTools's price volatility has been higher than the market average.
| Beta | 1.53 |
| 52-Week Price Change | -54.33% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.71 |
| Relative Strength Index (RSI) | 50.69 |
| Average Volume (20 Days) | 1.82M |
Income Statement
In the last 12 months, Standard BioTools had revenue of 174.43M and earned -138.88M in profits. Earnings per share was -0.52.
| Revenue | 174.43M |
| Gross Profit | 84.26M |
| Operating Income | -175.24M |
| Net Income | -138.88M |
| EBITDA | -118.14M |
| EBIT | -135M |
| Earnings Per Share (EPS) | -0.52 |
Balance Sheet
The company has 166.73M in cash and 33M in debt, giving a net cash position of 133.73M.
| Cash & Cash Equivalents | 166.73M |
| Total Debt | 33M |
| Net Cash | 133.73M |
| Retained Earnings | -1.19B |
| Total Assets | 612.34M |
| Working Capital | 309.99M |
Cash Flow
In the last 12 months, operating cash flow was -143.45M and capital expenditures -8.36M, giving a free cash flow of -151.81M.
| Operating Cash Flow | -143.45M |
| Capital Expenditures | -8.36M |
| Free Cash Flow | -151.81M |
| FCF Per Share | -0.43 |
Margins
Gross margin is 48.31%, with operating and profit margins of -100.46% and -79.62%.
| Gross Margin | 48.31% |
| Operating Margin | -100.46% |
| Pretax Margin | -79.29% |
| Profit Margin | -79.62% |
| EBITDA Margin | -67.73% |
| EBIT Margin | -100.46% |
| FCF Margin | -87.03% |
Dividends & Yields
LAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LAB is $2.5, which is 115.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $2.5 |
| Price Target Difference | 115.5% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 1.97 |
| Piotroski F-Score | 1 |